Skip to main content
Clinical Trials/NCT01825993
NCT01825993
Unknown
Phase 3

RANDOMISED STUDY ABOUT POTSOTERATORY PAIN CONTROL IN LAPAROSCOPIC SIGMOIDECTOMY

Corporacion Parc Tauli1 site in 1 country225 target enrollmentApril 2013

Overview

Phase
Phase 3
Intervention
MORPHINE
Conditions
Sigmoidal Tumour
Sponsor
Corporacion Parc Tauli
Enrollment
225
Locations
1
Primary Endpoint
EVA (POSTOPERATIVE PAIN)
Last Updated
13 years ago

Overview

Brief Summary

The investigators would study the control of postoperative pain with peridural catheter, morphine PCA ev or Transabdominal block.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
April 2015
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Corporacion Parc Tauli
Responsible Party
Principal Investigator
Principal Investigator

LAURA MORA LOPEZ

General Surgeon

Corporacion Parc Tauli

Eligibility Criteria

Inclusion Criteria

  • Age more than 18
  • Laparoscopic sigmoidectomy
  • Informed consent firmed

Exclusion Criteria

  • Urgent surgery
  • Sigmoid tumour stage IV
  • Cronic pain treatment
  • No informed consent firmed
  • Paliative surgery

Arms & Interventions

PCA endovenous

1mg/10 min Morphine

Intervention: MORPHINE

PERIDURAL CATHETER

Peridural L-bupivacaine 0.25%

Intervention: L-BUPIVACAINE ; MORPHINE

TANSABDOMINAL BLOCK (TAP)

L-BUPIVACAINE im

Intervention: L-BUPIVACAINE ; MORPHINE

Outcomes

Primary Outcomes

EVA (POSTOPERATIVE PAIN)

Time Frame: 72 H POSTOPERATIVE

The investigators asked the patient the postoperative pain during teh first 72 hours by EVA scale.

Secondary Outcomes

  • ADVERSE EFFECTS(five days)

Study Sites (1)

Loading locations...

Similar Trials